Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Relacorilant is a glucocorticoid receptor antagonist.
Relacorilant was approved for medical use in the United States in March 2026.
Relacorilant is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Relacorilant is under development by Corcept Therapeutics for the treatment of Cushing's syndrome and overian cancer.